OBJECTIVES: This study seeks to determine if variation in the dopamine transporter gene (SLC6A3/DAT1) moderates the dose-response effects of long-acting dexmethylphenidate (D-MPH) and mixed amphetamine salts (MAS) in children with attention-deficit/hyperactivity disorder (ADHD). METHODS:Fifty-six children and adolescents (mean age=11.7±2.2) participated in a double-blind, two period crossover, dose-response study with a randomized placebo week in each 4 week drug period. Each period consisted of sequential week-long exposures to three dose levels (10, 20, 25-30 mg, depending upon weight) of D-MPH or MAS. RESULTS: Doses of 10-20 mg of either D-MPH or MAS had little to no effect on hyperactivity-impulsivity and total ADHD symptom scores in subjects with the 9/9 genotype; this was in contrast to the dose-response curves of subjects with either the 10/10 or 10/9 genotype. CONCLUSIONS: ADHD youth with the 9/9 genotype may require higher stimulant doses to achieve adequate symptom control.
RCT Entities:
OBJECTIVES: This study seeks to determine if variation in the dopamine transporter gene (SLC6A3/DAT1) moderates the dose-response effects of long-acting dexmethylphenidate (D-MPH) and mixed amphetamine salts (MAS) in children with attention-deficit/hyperactivity disorder (ADHD). METHODS: Fifty-six children and adolescents (mean age=11.7±2.2) participated in a double-blind, two period crossover, dose-response study with a randomized placebo week in each 4 week drug period. Each period consisted of sequential week-long exposures to three dose levels (10, 20, 25-30 mg, depending upon weight) of D-MPH or MAS. RESULTS: Doses of 10-20 mg of either D-MPH or MAS had little to no effect on hyperactivity-impulsivity and total ADHD symptom scores in subjects with the 9/9 genotype; this was in contrast to the dose-response curves of subjects with either the 10/10 or 10/9 genotype. CONCLUSIONS:ADHD youth with the 9/9 genotype may require higher stimulant doses to achieve adequate symptom control.
Authors: Mark A Bellgrove; Ziarih Hawi; Aiveen Kirley; Michael Fitzgerald; Michael Gill; Ian H Robertson Journal: Neuropsychopharmacology Date: 2005-12 Impact factor: 7.853
Authors: James J McGough; James T McCracken; Sandra K Loo; Marc Manganiello; Michael C Leung; Jeremy R Tietjens; Thao Trinh; Shilpa Baweja; Robert Suddath; Susan L Smalley; Gerhard Hellemann; Catherine A Sugar Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-12 Impact factor: 8.829
Authors: Christopher P King; Abraham A Palmer; Leah C Solberg Woods; Larry W Hawk; Jerry B Richards; Paul J Meyer Journal: Psychopharmacology (Berl) Date: 2016-05-05 Impact factor: 4.530